Immunsys Is A Clinical Stage Biopharmaceutical Company Focused On The Development Of Innovative Cancer Immunotherapy Products To Improve The Lives Of Patients With Late Stage Metastatic Prostate Cancer And Other Metastatic Solid Tumor Cancers Immunsys Is At The Forefront Of An Entirely New Approach To Treating Cancerour Platform Therapy Has Been Shown To Be Effective In Some Metastatic Cancers And May Have Wide Applications As A Cancer Treatment For Several Solid Tumor Cancerswith The Potential For Cure In Some Patientsthe Company S Revolutionary Therapyyourvaccxa C Utilizes A Novel Combination Of Controlled Cell Lysis And A Triple Component Immunotherapeutic Drug This New Immunotherapy Focused Therapy Is Designed To Empower The Immune System To Recognize And Selectively Attack Cancer Cells Throughout The Bodythe Company Is Initially Developing The New Cancer Therapy For The Treatment Of Metastatic Prostate Cancerwith Apipeline Of Additional Development Programs For Other Solid Tumor Cancers Our Proprietary Therapy Was Conceived By The Focal Prostate Cancer Therapy Pioneer And Inventor Of The Male Lumpectomygary Onikm Dhe Is Not Only The Inventorbut Also A Patientdronik Developed Aggressive Metastatic Prostate Cancer In 2018 And Received His Own Therapyhe Had A Complete Response And Remains Disease Free To Date Immunsys Is Committed To Bringing Life Changing Treatments To Cancer Patients By Bringing The Tumor To The Immune System To Fight Cancer In A New Waywe Believe Our New Yourvaccxa C Therapy Has The Potential To Offer Cancer Patients Substantial Benefits Over The Existing Standard Of Careincluding The Potential For Cure In Some Patients
